Vaccine News and Research

Latest Vaccine News and Research

Can the absence of evidence of in-school SARS-CoV-2 transmission be taken as evidence of absence?

Research by scientists at the University of Texas at Austin, the Santa Fe Institute, and Fractal Therapeutics suggests infection rates in the surrounding community are not a reliable measure for estimating the level of risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission in schools.

4 May 2021

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Moderna has announced Emergency Use Listing granted by the World Health Organization for its COVID-19 mRNA vaccine.

4 May 2021

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

A vexing problem in the development of vaccines has been the need to achieve the right glycosylation profile for the viral antigens. A new study, recently released as a preprint on the bioRxiv* server, shows how a sequential cell-free approach produced complex N-glycans from simpler types, in a one-pot reaction.

4 May 2021

Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults

After spending much of the past year tending to elderly patients, doctors are seeing a clear demographic shift: young and middle-aged adults make up a growing share of the patients in covid-19 hospital wards.

4 May 2021

Conspiracies beliefs about COVID-19 increased among users of conservative and social media

Belief in conspiracies about the COVID-19 pandemic increased through the early months of the U.S. outbreak among people who reported being heavy users of conservative and social media, a study by Annenberg Public Policy Center (APPC) researchers has found.

4 May 2021

Rapid and sensitive SARS-CoV-2 detection from saliva using CRISPR

In a paper recently uploaded to the preprint server medRxiv by Edward Málaga Trillo et al. (April 29th, 2021), these methods are tested in combination with CRISPR-Cas detection in the field, demonstrating a sensitivity and specificity of 93.8% and 99%, respectively.

4 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

Researchers in the United States and India have conducted a study demonstrating the real-world effectiveness of a single dose of Johnson & Johnson’s Ad26.COV2.S vaccine at preventing infection with severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

3 May 2021

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

A team of scientists from the United States has recently investigated the robustness and durability of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) patients. Their findings reveal that COVID-19 patients exhibit a strong anti-SARS-CoV-2 antibody response for up to 1 year and that the robustness of antibody response depends on the patient’s age and disease severity.

3 May 2021

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

A new study, released as a preprint on the bioRxiv* server, reports promising results with the natural product hopeaphenol, which successfully prevented the entry of the virus into host cells.

3 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Detecting rare blood clots was a win, but US vaccine safety system still has gaps

The quick detection of an ultra-rare blood clotting reaction in some Covid-19 vaccine recipients showed the power of a federal warning system for vaccine safety issues, but experts worry that blind spots in the program could hamper detection of other unexpected side effects.

3 May 2021

CVS and Walgreens have wasted more vaccine doses than most states combined

Two national pharmacy chains that the federal government entrusted to inoculate people against Covid-19 account for the lion's share of wasted vaccine doses, according to government data obtained by KHN.

3 May 2021

As vaccine demand slows, political differences go on display in California Counties

Demand for Covid vaccines is slowing across most of California, but as traffic at vaccination sites eases, the vaccination rates across the state are showing wide disparities.

3 May 2021

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

New research published in the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases has confirmed the emergence of a new SARS-CoV-2 variant called HMN.19B from the viral clade 19B in France. The 19B viral clade — which includes the D614G variant — was prevalent in late 2019 but had since been rarely observed since early 2020 because of newer viral clades.

3 May 2021

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

Study reveals new broadly neutralizing and protective antibody against coronaviruses

In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047.

3 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Researchers in the United States have conducted a study demonstrating the effectiveness of first-generation vaccines at protecting against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals who have previously been infected with the virus.

2 May 2021

Vaccine News and Research

Latest Vaccine News and Research

Can the absence of evidence of in-school SARS-CoV-2 transmission be taken as evidence of absence?

Moderna COVID-19 vaccine makes it on WHO Emergency Use Listing

Could in vitro glycoengineering help produce better SARS-CoV-2 spike candidates for vaccine research?

Covid ‘doesn’t discriminate by age’: Serious cases on the rise in younger adults

Conspiracies beliefs about COVID-19 increased among users of conservative and social media

Rapid and sensitive SARS-CoV-2 detection from saliva using CRISPR

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers demonstrate real-world effectiveness of Johnson & Johnson COVID-19 vaccine

SARS-CoV-2 antibodies are detectable up to a year after infection, finds study

Hopeaphenol inhibits entry of SARS-CoV-2 variants of concern into cells

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Detecting rare blood clots was a win, but US vaccine safety system still has gaps

CVS and Walgreens have wasted more vaccine doses than most states combined

As vaccine demand slows, political differences go on display in California Counties

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Study reveals new broadly neutralizing and protective antibody against coronaviruses

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants of concern

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in